These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 11357498)
21. Successful and unsuccessful approaches to imaging carcinoids: comparison of a radiolabelled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue. Macfarlane D; Gonin J; Wieland D; Mangner T; Froelich J; Beierwaltes W; Shapiro B Eur J Nucl Med; 1996 Feb; 23(2):131-40. PubMed ID: 8925846 [TBL] [Abstract][Full Text] [Related]
22. 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET. Lubberink M; Tolmachev V; Widström C; Bruskin A; Lundqvist H; Westlin JE J Nucl Med; 2002 Oct; 43(10):1391-7. PubMed ID: 12368379 [TBL] [Abstract][Full Text] [Related]
23. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Kaltsas GA; Mukherjee JJ; Grossman AB Ann Oncol; 2001; 12 Suppl 2():S47-50. PubMed ID: 11762352 [TBL] [Abstract][Full Text] [Related]
24. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy. Lastoria S; Vergara E; Palmieri G; Acampa W; Varrella P; Caracò C; Bianco RA; Muto P; Salvatore M J Nucl Med; 1998 Apr; 39(4):634-9. PubMed ID: 9544670 [TBL] [Abstract][Full Text] [Related]
25. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448 [TBL] [Abstract][Full Text] [Related]
26. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519 [TBL] [Abstract][Full Text] [Related]
27. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Adams S; Baum RP; Hertel A; Schumm-Dräger PM; Usadel KH; Hör G Nucl Med Commun; 1998 Jul; 19(7):641-7. PubMed ID: 9853344 [TBL] [Abstract][Full Text] [Related]
28. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. Koopmans KP; Jager PL; Kema IP; Kerstens MN; Albers F; Dullaart RP J Nucl Med; 2008 Aug; 49(8):1232-7. PubMed ID: 18632829 [TBL] [Abstract][Full Text] [Related]
29. Nuclear medicine imaging of neuroendocrine tumours. Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353 [TBL] [Abstract][Full Text] [Related]
30. Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography. Michałowska I; Ćwikła JB; Pęczkowska M; Furmanek MI; Buscombe JR; Michalski W; Prejbisz A; Szperl M; Malinoc A; Moczulski D; Szutkowski Z; Kawecki A; Antoniewicz J; Pęczkowski P; Lewczuk A; Otto M; Cichocki A; Bednarek-Tupikowska G; Kabat M; Janaszek-Sitkowska H; Przybyłowska K; Janas J; Neumann HP; Januszewicz A Neuroendocrinology; 2015; 101(4):321-30. PubMed ID: 25791839 [TBL] [Abstract][Full Text] [Related]
31. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. Tenenbaum F; Lumbroso J; Schlumberger M; Mure A; Plouin PF; Caillou B; Parmentier C J Nucl Med; 1995 Jan; 36(1):1-6. PubMed ID: 7799058 [TBL] [Abstract][Full Text] [Related]
32. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors. Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731 [TBL] [Abstract][Full Text] [Related]
33. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Pfannenberg AC; Eschmann SM; Horger M; Lamberts R; Vonthein R; Claussen CD; Bares R Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):835-43. PubMed ID: 12682789 [TBL] [Abstract][Full Text] [Related]
34. Octreotide scanning for carcinoid tumours. Critchley M Postgrad Med J; 1997 Jul; 73(861):399-402. PubMed ID: 9338023 [TBL] [Abstract][Full Text] [Related]
35. Comparison of 131I-MIBG, 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT scans in a patient with extra adrenal paraganglioma associated with SDH-B gene mutation. Kasaliwal R; Malhotra G; Lila A; Bandgar T; Shah NS Clin Nucl Med; 2015 May; 40(5):439-41. PubMed ID: 25742231 [TBL] [Abstract][Full Text] [Related]
36. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1. Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985 [TBL] [Abstract][Full Text] [Related]
37. [The scintigraphy of somatostatin receptors in the carcinoid tumor]. Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324 [TBL] [Abstract][Full Text] [Related]
38. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. Sharma P; Thakar A; Suman K C S; Dhull VS; Singh H; Naswa N; Reddy RM; Karunanithi S; Kumar R; Kumar R; Malhotra A; Bal C J Nucl Med; 2013 Jun; 54(6):841-7. PubMed ID: 23520216 [TBL] [Abstract][Full Text] [Related]
39. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours. Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123 [TBL] [Abstract][Full Text] [Related]
40. Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide. Kaltsas GA; Putignano P; Mukherjee JJ; Satta MA; Lowe DG; Britton KE; Monson JP; Grossman AB; Besser GM Clin Endocrinol (Oxf); 1998 Nov; 49(5):685-9. PubMed ID: 10197087 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]